Bevacizumab for Glioblastoma—A Promising Drug or Not?

Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagane, Motoo, Nishikawa, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875948/
https://www.ncbi.nlm.nih.gov/pubmed/24213559
http://dx.doi.org/10.3390/cancers5041456
_version_ 1782297437007773696
author Nagane, Motoo
Nishikawa, Ryo
author_facet Nagane, Motoo
Nishikawa, Ryo
author_sort Nagane, Motoo
collection PubMed
description Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but also looking beyond.
format Online
Article
Text
id pubmed-3875948
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38759482013-12-31 Bevacizumab for Glioblastoma—A Promising Drug or Not? Nagane, Motoo Nishikawa, Ryo Cancers (Basel) Review Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but also looking beyond. MDPI 2013-11-07 /pmc/articles/PMC3875948/ /pubmed/24213559 http://dx.doi.org/10.3390/cancers5041456 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Nagane, Motoo
Nishikawa, Ryo
Bevacizumab for Glioblastoma—A Promising Drug or Not?
title Bevacizumab for Glioblastoma—A Promising Drug or Not?
title_full Bevacizumab for Glioblastoma—A Promising Drug or Not?
title_fullStr Bevacizumab for Glioblastoma—A Promising Drug or Not?
title_full_unstemmed Bevacizumab for Glioblastoma—A Promising Drug or Not?
title_short Bevacizumab for Glioblastoma—A Promising Drug or Not?
title_sort bevacizumab for glioblastoma—a promising drug or not?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875948/
https://www.ncbi.nlm.nih.gov/pubmed/24213559
http://dx.doi.org/10.3390/cancers5041456
work_keys_str_mv AT naganemotoo bevacizumabforglioblastomaapromisingdrugornot
AT nishikawaryo bevacizumabforglioblastomaapromisingdrugornot

Ejemplares similares